Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: A meta-analysis

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 342-346

  Zhu, Bing ^a   Wang, Liang ^a   Sun, Lan ^b   Cao, Ruihua ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

combination therapy; meta analysis; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; TREPROSTINIL;

ADD ON THERAPY; ARTICLE; DRUG EFFECT; EXERCISE; HOSPITALIZATION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN;

EID: 84867742487     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318262a793     Document Type: Article

References (20)

1. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278.
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
3. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165.
4. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
5. Benza RL, Park MH, Keogh A, et al. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007;26:437-446.
6. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
8. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
9. Irwig L, Macaskill P, Berry G, et al. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 1998; 316:470.
10. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359.
11. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
12. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691-694.
13. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to longterm intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med. 2008;149:521-530.
14. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
15. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124-1131.
16. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915-1922.
17. Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: The role of clinical worsening. Curr Opin Pulm Med. 2010;16(suppl 1):S1-S9.
18. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
19. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-2294.
20. Bai Y, Sun L, Hu S, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120:157-165.